EUVIMEDEUVIMED entdecken
Crossref

Management of Orthostatic Hypotension

David Moloney, Ayman Youssef, Luis E Okamoto

JAMA Internal Medicine · 01.06.2026 · 186 (6) · 744

DOI: 10.1001/jamainternmed.2026.0284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.06.2026. Verfasst von David Moloney und 2 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt Autonomic Dysfunction Center, Division of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt University Medica…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 111 Literaturangaben. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Orthostatic hypotension is a common but underrecognized condition that increases with age and is associated with a lower quality of life, falls, and increased mortality. The frequent coexistence of supine hypertension and postprandial hypotension with orthostatic hypotension makes it a challenging condition to manage. Observations Testing for orthostatic hypotension should be done in patients with orthostatic symptoms (eg, vision changes and dizziness that occur only when upright and improve when seated or lying down), as well as asymptomatic patients in high-risk groups such as adults with frailty who are older than 70 years, individuals with neurodegenerative or autonomic disorders, and patients with unexplained falls. Patients with orthostatic hypotension should be screened for postprandial hypotension and supine hypertension to inform the treatment approach. Nonpharmacological strategies, such as medication review, increased salt and fluid intake, compression garments, and behavioral modifications, serve as fundamental approaches to treat orthostatic hypotension. Midodrine and droxidopa are the only US Food and Drug Administration–approved medications for orthostatic hypotension, but other medications (eg, fludrocortisone, atomoxetine, pyridostigmine) are used off label as part of an individualized treatment plan. Treatment targets in orthostatic hypotension are focused not on blood pressure measurements but on symptom relief and fall prevention. Conclusions and Relevance All patients with orthostatic symptoms—along with other select patient groups—should be evaluated for orthostatic hypotension. Nonpharmacological treatments are first line, and medication decisions should be tailored based on clinical presentation and relevant comorbidities.

Autor:innen und Institutionen

  • Vanderbilt Autonomic Dysfunction Center, Division of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Moloney, D., Youssef, A., & Okamoto, L. E. (2026). Management of Orthostatic Hypotension. JAMA Internal Medicine, 186(6), 744. https://doi.org/10.1001/jamainternmed.2026.0284

Vancouver

Moloney D, Youssef A, Okamoto LE. Management of Orthostatic Hypotension. JAMA Internal Medicine. 2026;186(6):744. doi:10.1001/jamainternmed.2026.0284

BibTeX
@article{Moloney2026,
  author = {Moloney, David and Youssef, Ayman and Okamoto, Luis E},
  title = {Management of Orthostatic Hypotension},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {6},
  pages = {744},
  doi = {10.1001/jamainternmed.2026.0284}
}
Kostenlos starten →